Erythropoietin (EPO) Market Trends, Growth, Share, Outlook, Opportunities, Analysis And Forecast 2033

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patient education and awareness, pharmaceutical industry consolidation, healthcare reimbursement policies, market expansion and demand growth, patent expiration and biosimilar entry.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to market competition and biosimilar impact, disease prevalence projections, healthcare policy and reimbursement changes, emerging markets growth, clinical trials and research focus. Major trends in the forecast period include supply chain management, global expansion and emerging markets, patient education and awareness, reimbursement policies, market consolidation and mergers.

Market Overview -
Erythropoietin (EPO) refers to a glycoprotein hormone that naturally induces the generation of red blood cells and is produced by the kidney's peritubular cells. Red blood cell scarcity, or anaemia, is treated with it. Weakness, weariness, and shortness of breath are signs of anaemia because red blood cells deliver oxygen to the tissues and organs.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3436&type=smp

Erythropoietin Market Gains Momentum Amid Rising Incidence Of Chronic Kidney Diseases
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the coming years. The growing cases of chronic kidney disease require erythropoietin administration, which is used to make red blood cells to improve immunity. For instance, in March 2021, according to the Centers for Disease Control and Prevention's report published on chronic kidney disease in the United States, 15% of the adults in the USA, or 37 million people, were estimated to have chronic kidney disease (CKD). People aged 65 or older are more likely to have CKD (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%). Chronic kidney diseases lead to an anaemic condition, which in turn increases the demand for erythropoietin to curb the condition, thereby driving the market revenues.

Competitive Landscape -
Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods plc, DuPont de Nemours Inc., Kerry Group plc, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International plc, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

Elanco's Varenzin-Ca1 Revolutionizes Anemia Treatment For Cats With Chronic Kidney Disease
Major companies operating in the erythropoietin market are developing innovative products such as Varenzin-CA1 to mark their position in the market. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. For instance, in May 2023, Elanco, a US-based pharmaceutical company received FDA approval for Varenzin-CA1. It is developed exclusively for cats and features a mode of action that induces the genetic transcription of erythropoietin (EPO), increasing both EPO and red blood cell production in a cat's body. Varenzin-CA1 is a breakthrough innovation that meets at-home convenience and sets a new standard of care for cats suffering from nonregenerative anemia due to CKD.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/erythropoietins-global-market-report

Key Segments -
The erythropoietin (epo) market covered in this report is segmented -
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologis, Biosimilar
3) By Application: Cancer, Hematology, Renal diseases, Neurology, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.